Advertisement

Anxiety Disorder Due to a General Medical Condition

  • James D. Helsley
Chapter
  • 1.7k Downloads
Part of the Current Clinical Practice book series (CCP)
Anxiety disorders are the most prevalent mental disorders in the United States. The economic burden is estimated to be nearly $50 billion annually [1]. The most common anxiety disorders are as follows:
  • Generalized anxiety disorder (GAD)

  • Panic disorder (PD)

  • Obsessive-compulsive disorder (OCD)

  • Phobias/social anxiety disorder

  • Posttraumatic stress disorder (PTSD)

  • Acute stress disorder

  • Anxiety disorder due to a medical condition

  • Anxiety disorder induced by a substance

The exact cause of the anxiety disorders is unknown. There is, however, considerable evidence that a deep brain structure, the amygdala, is intricately involved with the development of anxiety behavior. The amygdala is thought to mediate the fear response in the brain when an individual is confronted with real or perceived danger [2]. The response of the amygdala to a threat is to create the “fight or flight” response, which includes adrenal catecho-lamine release, increased heart rate, glycogenolysis, and shunting of blood...

Keywords

Chronic Obstructive Pulmonary Disease Irritable Bowel Syndrome Anxiety Disorder Anxiety Symptom Chronic Obstructive Pulmonary Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Marciniak M, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depression and Anxiety 2005;21:178–184.CrossRefPubMedGoogle Scholar
  2. 2.
    Dolnak D. Treating patients for comorbid depression, anxiety disorders, and somatic illness. JAOA 2006;106(5, suppl 2):S1–8.PubMedGoogle Scholar
  3. 3.
    First M, Frances A, Pincus H. Anxiety disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision (DSM-IV-TR). Washington, DC: American Psychiatric Publishing, 2002:163–181.Google Scholar
  4. 4.
    Drooker M. Other cognitive disorders and mental disorders due to a general medical condition. In: Sadock B, Sadock V, eds. Comprehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams & Wilkins, 2005:1106–1136.Google Scholar
  5. 5.
    Chesnutt M, Prendergast T. Lung. In: Tierney L, McPhee S, Papadakis M, eds. Current Medical Diagnosis and Treatment. New York: McGraw-Hill, 2006:218–311.Google Scholar
  6. 6.
    Roundy K, et al. Are anxiety and depression addressed in primary care patients with chronic obstructive pulmonary disease. J Clin Psychiatry Prim Care Companion 2005;7(5):213–217.Google Scholar
  7. 7.
    Hu J, Meek P. Health-related quality of life in individuals with chronic obstructive pulmonary disease. Heat Lung 2005;34(6):415–422.CrossRefGoogle Scholar
  8. 8.
    Lavoie K, et al. Are psychiatric disorders associated with worse asthma control and quality of life in asthma patients? Respir Med 2005;99:1249–1257.CrossRefPubMedGoogle Scholar
  9. 9.
    Hoffman B, Lefkowitz R. Catecholamines and sympathomimetic drugs. In: Goodman A, Gilman A, Rall T, Nies A, Taylor P, eds. The Pharmacologic Basis of Therapeutics. Elmsford, NY: Pergamon Press, 1990:187–220.Google Scholar
  10. 10.
    Kayani S, Shannon D. Adverse behavioral effects of treatment for acute exacerbations of asthma in children: a comparison of two doses of oral steroids. Chest 2002;122:624–628.CrossRefPubMedGoogle Scholar
  11. 11.
    Thom T, et al. Heart disease and stroke statistics—2006 update. Circulation 2006;113:e85–e151.CrossRefPubMedGoogle Scholar
  12. 12.
    Bashore T, Granger C. Heart. In: Tierney L, McPhee S, Papadakis M, eds. Current Medical Diagnosis and Treatment. New York: McGraw-Hill, 2006:312–418.Google Scholar
  13. 13.
    Haworth J, et al. Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction. Eur J Heart 2005;7(5):803–808.CrossRefGoogle Scholar
  14. 14.
    Jaing W, et al. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation 2004;110(22):3452–3456.CrossRefGoogle Scholar
  15. 15.
    Moser D, Doering L, Chung M. Vulnerabilities of patients recovering from an exacerbation of chronic heart failure. Am Heart J 2005;150(5):984.e7–13.CrossRefGoogle Scholar
  16. 16.
    Abbott A. Diagnostic approach to palpitations. Am Fam Physician 2005;71(4):743–750.PubMedGoogle Scholar
  17. 17.
    Tata L, et al. General population based study of the impact of tri-cyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005;91:465–471.CrossRefPubMedGoogle Scholar
  18. 18.
    Roose S, Miyazaki M. Pharmacologic treatment of depression in patients with heart disease. Psychosom Med 2005;67(S1):s54–57.CrossRefPubMedGoogle Scholar
  19. 19.
    Schlienger R, Meier C. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs 2003;3(3):149–162.CrossRefPubMedGoogle Scholar
  20. 20.
    Fitzgerald P. Endocrinology. In: Current Medical Diagnosis and Treatment. New York: McGraw-Hill, 2006:1098–1193.Google Scholar
  21. 21.
    Stern R, et al. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996;8(2):181–185.PubMedGoogle Scholar
  22. 22.
    Sajatovic M, Ramirez L. Rating Scales in Mental Health. Hudson, OH: Lexi-Comp, 2003.Google Scholar
  23. 23.
    Iacovides A, et al. Difference in symptom profile between generalized anxiety disorder and anxiety secondary to hyperthyroidism. Int J Psychiatry Med 2000;30(1):71–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Broderick P, Benjamin A. Caffeine and psychiatric symptoms: a review. J Okla State Med Assoc 2004;97(12):538–542.PubMedGoogle Scholar
  25. 25.
    Walker R, Lupien J. The safety evaluation of monosodium glutamate. J Nutr 2000;130:1049s–1052s.PubMedGoogle Scholar
  26. 26.
    Ostir G, Goodwin J. High anxiety is associated with an increased risk if death in an older tri-ethnic population. J Clin Epidemiol 2006;59:534–540.CrossRefPubMedGoogle Scholar
  27. 27.
    Cohen S, Block S. Issues in psychotherapy with terminally ill patients. Palliat Support Care 2004;2(2):181–189.CrossRefPubMedGoogle Scholar
  28. 28.
    Stephenson P. Before the teaching begins: managing patient anxiety prior to providing education. Clin J Oncol Nurs 2006;10(2):241–245.CrossRefPubMedGoogle Scholar
  29. 29.
    Spiller R. Irritable bowel syndrome. Br Med Bull 2005;72:15–29.CrossRefGoogle Scholar
  30. 30.
    Sagami Y, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53(7):958–964.CrossRefPubMedGoogle Scholar
  31. 31.
    Folks D. The interface of psychiatry and irritable bowel syndrome. Curr Psychiatry Rep 2004;6(3):210–215.CrossRefPubMedGoogle Scholar
  32. 32.
    Haus U, Spath M, Farber L. Spectrum of use and tolerability of 5—HT3 receptor antagonists. Scand J Rheumatol Suppl 2004;119:12–18.CrossRefPubMedGoogle Scholar
  33. 33.
    Jackson J, O'Malley P, Kroenke K. Antidepressants and cognitive behavioral therapy for symptom syndromes. CNS Spectrums 2006;11(3):212–222.PubMedGoogle Scholar
  34. 34.
    Chan P, Thomas D, McKinley E, Stanford E. Outpatient and Primary Care. Laguna Hills, CA: Current Clinical Strategies Publishing, 2005:232–255.Google Scholar

Copyright information

© Humana Press 2008

Authors and Affiliations

  • James D. Helsley
    • 1
  1. 1.West Virginia University Student Health ServiceMorgantownUSA

Personalised recommendations